Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2559595 | 0.87 | MAPK1 (0.70) | KDM4EMAPK1TSHRCYP1A2CYP3A4 | |
| SCHEMBL31737057 | 0.87 | KDM4E (0.74) | KDM4EMAPK1PDE4BTSHRCA12 | |
| SCHEMBL9305217 | 0.87 | KDM4E (0.74) | KDM4EMAPK1PDE4BTSHRCYP1A2 | |
| SCHEMBL29537569 | 0.87 | KDM4E (0.74) | KDM4EMAPK1PDE4BTSHRCYP1A2 | |
| SCHEMBL14907128 | 0.87 | KDM4E (0.74) | KDM4EMAPK1PDE4BTSHRCA12 | |
| SCHEMBL3547607 | 0.85 | KDM4E (0.72) | KDM4EMAPK1PDE4BTSHRCYP1A2 | |
| SCHEMBL680755 | 0.84 | KDM4E (0.71) | KDM4EMAPK1PDE4BTSHRCYP1A2 | |
| SCHEMBL28326914 | 0.84 | KDM4E (1.00) | KDM4EMAPK1PDE4BTSHRCYP1A2 | |
| SCHEMBL31737297 | 0.84 | KDM4E (0.71) | KDM4EMAPK1PDE4BTSHRCYP1A2 | |
| SCHEMBL8484361 | 0.84 | KDM4E (0.66) | KDM4EMAPK1PDE4BTSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172246-A1 | Dietary Composition and Method | CAPSUGEL BELGIUM NV (BE) | 2023-06-08 | — | — | US | disclosed |
| EP-4152939-A1 | DIETARY COMPOSITION AND METHOD | Capsugel Belgium NV (BE) | 2023-03-29 | — | — | EP | disclosed |
| WO-2022006200-A1 | DIETARY COMPOSITION AND METHOD | CAPSUGEL BELGIUM NV (BE) | 2022-01-06 | — | — | WO | disclosed |
| US-20170007591-A1 | Composition to Mitigate Spikes in Blood Sugar | ATM METABOLICS, LLC | 2017-01-12 | — | — | US | disclosed |
| US-8987328-B2 | Esters of capsaicinoids as dietary supplements | TRINITY LABORATORIES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8765807-B2 | Esters of capsaicin for treating pain | TRINITY LABORATORIES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140134261-A1 | Pharmaceutical Compositions Comprising Capsaicin Esters for Treating Pain and Cold Sores | TRINITY LABORATORIES, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20110218180-A1 | Esters of Capsaicin for Treating Pain | Trinity Laboratiories, Inc. (US) | 2011-09-08 | — | — | US | disclosed |
| US-7943666-B2 | Esters of capsaicin for treating pain | TRINITY LABORATORIES, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7867526-B2 | Composition for weight reduction comprising capsaicin, green tea extract, L-tyrosine and caffeine | IDEASPHERE, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-5959186-A | No-heat Jalapenos | CAMPBELL SOUP COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| US-5869533-A | POLYMERIC BASE, POLYOL, ADHESIVE AND PLANT EXTRACT | MEDICAL MERCHANDISING, INC. | 1999-02-09 | — | — | US | disclosed |
| US-5856361-A | CAPSAICIN PLUS PLANT EXTRACT ANALGESIC | MEDICAL MERCHANDISING, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5854291-A | Pain reliever and method of use | MEDICAL MERCHANDISING, INC. (US) | 1998-12-29 | — | — | US | disclosed |
| WO-1998047376-A1 | NUTRITIVE COMPOSITION FOR CARDIOVASCULAR HEALTH | VIVA AMERICA MARKETING, INC. (US) | 1998-10-29 | — | — | WO | disclosed |
| EP-0835119-A4 | FISH OIL AND GARLIC NUTRITIVE COMPOSITION | VIVA AMERICA MARKETING INC (US) | 1998-08-26 | — | — | EP | disclosed |
| US-5762963-A | DISPERSING IN SOLID OR GEL VEHICLE IN WHICH CONCENTRATION OF CAPSAICINOID DECREASES FROM CENTER TOWARD PERIPHERY; FOR MOUTH, THROAT PAIN RELIEF | EMORY UNIVERSITY (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0835119-A1 | FISH OIL AND GARLIC NUTRITIVE COMPOSITION | Viva America Marketing, Inc. (US) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997033599-A1 | FISH OIL AND GARLIC NUTRITIVE COMPOSITION | VIVA AMERICA MARKETING, INC. (US) | 1997-09-18 | — | — | WO | disclosed |
| WO-1996040079-A1 | METHOD AND COMPOSITIONS FOR CONTROLLING ORAL AND PHARYNGEAL PAIN USING CAPSAICINOIDS | EMORY UNIVERSITY (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218180-A1 | Esters of Capsaicin for Treating Pain | FAAH, APEH, FFAR1 | KDM4E 2130/4885MAPK1 1727/4885PDE4B 2732/4885 |
| US-20140134261-A1 | Pharmaceutical Compositions Comprising Capsaicin Esters for Treating Pain and Cold Sores | TRPV1, ALOX12, OPRK1 | KDM4E 2015/4885MAPK1 2025/4885PDE4B 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.